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Overall prognosis in acute myeloid leukaemia (AML) is difficult
to predict from previous reports, since these are usually dealing
with selected cohorts of patients (Boros et al, 1985; The Toronto
Leukemia Study Group, 1986; Wahlin et al, 1991; Ferrara et al,
1998). Elderly patients are often excluded from treatment trials
for various reasons (The Toronto Leukemia Study Group, 1986;
Ferrara et al, 1998). Differences in referral patterns make overall
treatment results from specialized centres difficult to interpret
(Taylor et al, 1995). We know few studies attempting to give the
outcome of treatments on the basis of an epidemiologic definition
of AML. Even in these studies there is probably some selection of
patients, since they were based on cases treated at specialized
centres or reported to an official registry (Öst et al, 1984; Brincker,
1985; Wahlin et al, 1991; Proctor et al, 1995; Taylor et al, 1995).
It has been shown that official statistics of morbidity and mortality
is not always reliable concerning the total occurrence of haemato-
logical malignancies (Mattsson and Wallgren, 1984).
We decided to do a retrospective review of the treatment and
outcome of unselected adult AML patients in our geographical
region, including patients unreferred from district hospitals. By
using four independent registries, the coverage of patients has
been maximized. We also attempted to assess the prognostic value
of factors such as age, treatment, antecedent haematological
disorder and laboratory characteristics in this material.
MATERIALS AND METHODS
Population
The population base for this investigation consists of three counties
of similar size in central Sweden: Örebro, Södermanland and
Värmland. During the study period, 1987–1992, the total number
of inhabitants in this region rose from 797 960 to 816 874, of whom
657 397 and 667 496 respectively were 15 years or older. Children
under 15 years were not included in the investigation. The age
distribution was somewhat skewed compared to the national
average, with 24.5% over 60 years in our region compared with
22.8% in December 1989. Exact demographic data are available for
each year of the study period (Statistics Sweden, 1987–1992). All
patients with AML who were domiciled in any of the three counties
of the study were included, even those few who received treatment
at specialized clinics outside the geographical region.
Patients
Our method for case-finding consisted of a comparison of four
different registries: (1) The Swedish Cancer Registry, (2) The
Cause of Death Registry, (3) listings of pathology bone marrow
reports, and (4) listings of inpatient discharge diagnoses. All
included cases were adults found with newly diagnosed AML
1987–1992. Among secondary AML, only blast-crises of chronic
myeloid leukaemia (CML) were excluded, whereas leukaemias
secondary to other haematological conditions, chemotherapy or
irradiation were included. A total of 214 cases of AML were veri-
fied from medical records, corresponding to a mean yearly inci-
dence in adults of 5.4/100 000. The median age of the patients was
69.5 years. The age distribution is shown in Figure 1, with 74%
over 60 years at diagnosis, 52% over 70 years, 5% under 30 years.
Statistical methods
Study results were last updated on 31 December 1997. For the
evaluation of factors of importance for complete remission (CR)
frequency, contingency tables describing the CR frequency strati-
fied with respect to the investigated factors were analysed with
Fisher’s exact test. Prognostic factors for overall survival and CR
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comparing subgroups with the log-rank test. Prognostic variables
from univariate analyses were also entered into multivariate
analyses using Cox proportional hazard regression with a forward
stepwise selection procedure. Reduced kidney function was
defined as creatinine values above the upper reference limits in our
laboratory for males and females respectively. A P-value ≤ 0.05
was regarded as statistically significant in all analyses.
RESULTS
FAB classification and cytogenetics
The AML diagnoses were based upon stained bone marrow
smears in 210 cases where four were taken at autopsy, and
peripheral blood in four cases. Information about French–
American–British (FAB) class (Bennett et al, 1985) was found in
clinical records and bone marrow reports in 155 of the 214 AML
cases: M0 n = 3, M1 n = 40, M2 n = 47, M3 n = 9, M4 n = 33, M5
n = 19, M6 n = 3, M7 n = 1. Unclassified patients had a median age
of 74.9 years and the proportion of secondary AML was 41%
among these cases. Diagnostic confirmation by immunopheno-
typing and/or cytochemistry had been performed in 73% of ‘high-
dose’-treated patients, compared to 40% of ‘low-dose’-treated
patients and 9% of untreated patients. Cytogenetic examinations
had been successfully performed in 49 cases of whom 38 were
‘high-dose’-treated. A normal karyotype was found in 28 cases
and 21 had clonal abnormalities. Only three cases had transloca-
tions t(8;21) or t(15;17) which are related to good prognosis in
AML, but in these other abnormalities were present concomi-
tantly. Of patients under 60 years, 7/24 had chromosomal abnor-
malities compared to 14/25 of patients 60 years or older, with more
complex abnormalities in the oldest patients.
Secondary AML
Secondary AML was present in 48 cases with the median age 72.7
years, of whom 28 had histories of myelodysplastic syndromes
(MDS). Myeloproliferative disease, lymphoma or myeloma had
been present in 16 patients and four patients with antecedent solid
cancer forms had received irradiation treatment. In addition,
19 patients of whom 13 were over 60 years old had trilinear
dysplasia documented in bone marrow at diagnosis, without a
history of MDS.
Cytostatic treatment
One hundred and twenty patients with a median age of 61.1 years
had received ‘high-dose’ induction regimens aiming at obtaining
complete remissions, 60 ‘low-dose’ treatments and 34 only pallia-
tive care. Decisions to refrain from intensive chemotherapy in
many elderly patients were made by individual doctors and their
patients. For ‘high-dose’-treated patients, induction therapy
consisted of ara-C in standard or intermediate doses (79 cases) or
doses over 1 g m–2 (41 cases) in combination with an anthracycline
or mitoxantrone (118 cases). In 107 courses also thioguanine or
etoposide was included.
Of 83 patients achieving CR, at least one consolidation course
was given to 43 patients. Four of these patients were also treated
with allogenic bone marrow transplantation (BMT) and seven
with autologous bone marrow transplantation (ABMT) in
first CR. The remaining 40 patients, mostly elderly, received
‘low-dose’ maintenance treatment with thioguanine (20–320 mg
week–1 orally given on 1–2 consecutive days) continued until
relapse or for at least 3 years in relapse-free patients. Of 61
relapses in the total material, 48 were treated with new ‘high-dose’
induction courses, in two cases followed by BMT and in three
cases by ABMT.
Of the 60 ‘low-dose’-treated patients, seven had received
reduced induction courses in order to avoid toxicity. The
remainder of the ‘low-dose’-treated patients had been managed
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Figure 1 Age distribution of 214 unselected AML cases from the Örebro
region of central Sweden diagnosed 1987–1992
Table 1 Treatment types in different age categories and corresponding CR frequencies, CR durations and survival
All ‘High-dose’ treatment ‘Low-dose’ treatment No treatment
Age n % CR frequency CR durationa Survivala % CR frequency CR durationa Survivala % Survivala
%%
–59 56 98 80 13.7 24.9 2 0 – 8.3 – –
60–69 55 78 84 7.0 10.4 13 14 0.9 4.6 9 0.2
70–79 70 29 60 6.1 8.6 50 3 2.3 2.7 21 0.2
80– 33 6 50 10.0 10.9b 52 6 7.9 2.4 42 0.4
All ages 214 56 67 10.1 11.4 28 5 2.3 2.9 16 0.3
aMedian values in months. bOnly two patients with survival times 0.3 and 21.5 months respectively.with palliative intention mainly with ara-C, thioguanine and
etoposide separately or in combination.
Outcome
Overall survival in all 214 patients without exclusions is shown in
Figure 2. Median survival was 5.8 months and the probability of
survival at 5 years was 9.3%. CR rate for all patients was
38.8% and the median duration of the first remission was 9.8
months. In the patients acheiving CR, median survival was
21.6 months compared to 1.8 months in those who did not
achieve CR.
When separated according to type of treatment and age it is
evident that patients receiving ‘high-dose’ induction chemo-
therapy had the best outcome (Table 1). The 120 ‘high-dose’-
treated patients had a CR rate of 67%, median CR duration
10.1 months and median survival 11.4 months. Only one patient
under 60 years of age received ‘low-dose’ treatment for MDS-
AML. In contrast, a majority of the patients over 70 years were
given ‘low-dose’ or no cytostatic treatment. For all the 60 ‘low-
dose’-treated patients, median survival was 2.9 months com-
pared to 0.3 months for patients receiving no chemotherapy
at all.
Age and prognosis
Survival according to age irrespective of treatment is illustrated in
Figure 3. The median survival time for 56 patients under 60 years
was 24.8 months compared to 3.1 months for 158 patients 60 years
or older. Survival times also differed significantly between ages
60–69, 70–79, and over 80 years. There were 55, 70 and 33
patients in these age groups with median survival times 8.4, 2.4
and 1 month respectively. Survival at 5 years was 45% in the
youngest age group under 30 years, 24% in patients 30–59 years,
5% in patients 60–69 years, 1% in those 70–79 years and 0%
above 80 years. The poorer survival in the elderly correlated with
both lower CR rates and shorter CR duration. Among patients
under 60 years the CR rate was 79% and CR duration 13.7 months.
In patients over 60 years the CR rate was 24% and CR duration
6.8 months.
Other prognostic variables
When specifically assessing the influence of variables on CR
frequency, CR duration and survival, only ‘high-dose’-treated
patients were included in the evaluation. There were no significant
differences in outcome depending on FAB class, whereas patients
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Figure 2 Overall survival for 214 unselected patients with AML in the Örebro region of central Sweden 1987–1992. Median age is 69.5 years, median survival
is 5.8 months, probability of survival at 5 years is 9.3%with chromosomal abnormalities had lower CR frequency
(P = 0.02) and survival (P = 0.02). Other factors with a negative
impact on CR frequency were age over 60 years (P = 0.01), pres-
ence of secondary AML (P = 0.05) and impaired kidney function
at diagnosis (P = 0.05). Overall survival was poorer in patients
over 60 years (P = 0.0002), with secondary AML (P = 0.04),
impaired kidney function (P = 0.05) or lactate dehydrogenase
(LDH) values above 25 mkat l–1 (P = 0.05). A leucocyte count
above 100 ´ 109 l–1 was statistically non-significant for shorter
survival (P = 0.07). A multivariate analysis was performed
concerning prognostic variables for survival, where results of
cytogenetics were excluded from the analysis due to many missing
cases. The included variables were age, LDH, leucocyte count,
kidney function and presence of de novo/secondary leukaemia.
The only prognostic variables found in the stepwise selection
procedure were age (P = 0.005), LDH (P = 0.02) and kidney func-
tion (P = 0.05).
Concerning CR duration, the only significant variable in both
univariate and multivariate analysis was treatment intensity in CR
where the 43 patients who received consolidation therapy fared
better than the 40 who were given ‘low-dose’ maintenance treat-
ment only (P < 0.0001). This was evident also in the higher age
group over 60 years. Median CR duration for all patients treated
with consolidation was 24.7 months compared to 5.4 months for
those who received ‘low-dose’ treatment in first CR.
Selection in specialized clinics
Survival of 149 patients treated at Örebro Medical Center Hospital
or in nine cases other specialized clinics was compared to survival
of 37 patients in two central hospitals and 28 patients in eight
district hospitals. The median age of the 149 patients treated in
specialized clinics was 66.0 years, compared to 75.4 years in
central hospitals and 79.3 years in district hospitals. The corre-
sponding median survival times were 8.3 months, 2.9 months and
1.5 months respectively. Of the 65 patients treated at non-special-
ized centres, only 12 received ‘high-dose’ induction treatments, all
at the Central Hospital in Karlstad, with no difference in survival
and treatment-related mortality compared to similar risk patients
treated in Örebro.
Early deaths
The frequency of ‘early death’, within 1 month from diagnosis in
‘high-dose’-treated patients was 10/120 or 8.3%. In four cases the
cause was intracerebral haemorrhages, all these patients having
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Figure 3 Overall survival in 214 unselected AML patients depending on age. The median survival was 24.8 months for patients under 60 years compared to
3.1 months in those 60 years or older. The difference in survival is significant (P < 0.0001)disseminated intravascular coagulation at diagnosis. Another
patient died of a cerebral thrombosis, possibly on the basis of
leucostasis at presentation. In two cases, myocardial infarction in
connection with induction therapy was the terminal cause of
death. One patient died on the second day of admission with respi-
ratory failure from rapidly proliferative leukaemia. Additionally,
two patients died of infection and of multiorgan failure respec-
tively.
DISCUSSION
Unlike most other studies of AML which are based on patients
treated at specialized hospitals, the present investigation is a retro-
spective review covering also patients unreferred to such centres.
Our aim was to describe the full clinical spectrum of AML as well
as referral patterns, treatment decisions and outcome. In another
part of our study we have documented an undernotification of
acute leukaemias in the Swedish Cancer Registry of 15.4% among
adults and inconsistent coding in an additional 8.1% for the same
period 1987–1992. Overall, we wanted to make a quality assess-
ment of the management of AML in our geographical region, as an
example of a method of evaluation.
In comparison with earlier studies of AML, our incidence figure
of 5.4/100 000 per year in adults is high. If the two patients under
15 years with AML from our region in the Cancer Registry
1987–1992 would be included in the calculation, the yearly inci-
dence for all ages would amount to 4.5/100 000. Official crude
incidence rates for AML from the Swedish Cancer Registry
1987–1992 were consistently in the range 3.1–3.4/100 000 per
year for the total Swedish population, with corresponding ‘world
standardized rates’ (WSR) of around 2.0/100 000. Studies from
other European countries often show similar incidence rates as
those from the Swedish Cancer Registry, for example a study from
England and Wales with 3.4/100 000 per year (McKinney et al,
1989). We believe that the higher incidence figure in our study,
achieved by utilizing multiple sources of notification, illustrates a
common problem of undernotification in Cancer Registries and
selection in clinical trials.
That AML is a disease predominantly of the elderly is known
from earlier studies, with more than half of the cases being diag-
nosed in patients over 60 years (Öst et al, 1984; Brincker, 1985;
McKinney et al, 1989; Wahlin et al, 1991). In the present investi-
gation, 74% of the patients were over 60 years. A rising incidence
of AML depending on the increasing longevity of the population is
to be expected in the future, necessitating a reconsideration of
treatment priorities and resource allocation where attention must
be given to solving the problems of treatment in elderly patients
(Taylor et al, 1995; Hoff et al, 1997).
Immunophenotyping and cytogenetics had been utilized in
approximately the same frequency at Örebro Medical Center
Hospital as in other studies from specialized centres in the near
time period (Wahlin et al, 1991; Bassan et al, 1992; Proctor et al,
1995; Taylor et al, 1995). A majority of all bone marrow speci-
mens were analysed in Örebro Medical Center Hospital by either
haematologists or haematopathologists, but in the period
1987–1989 specimens were also sent to another centre for cyto-
chemistry. From patients unreferred to our hospital, smaller
pathology departments at the two other central hospitals had the
responsibility for diagnostics on bone marrow material. In the total
material, FAB classification was not always attempted and espe-
cially in many MDS-AML cases not deemed to be of interest.
According to recent literature on AML, approximately 60–80%
of patients less than 60 years of age can be expected to achieve CR
(Rowe and Liesveld, 1996). For patients over 60 years, studies
report varying CR frequencies from 40 to 70% using comparable
induction regimens and essentially identical supportive treatment
(Löwenberg, 1996). Preselection of patients may have led to over-
optimistic results in some of these trials. In studies in which
consecutive patients have been evaluated, a less favourable but
more realistic reality exists in terms of CR attainment and survival
(The Toronto Leukemia Study Group, 1986; Bassan et al, 1992;
Baudard et al, 1994).
In our material of unselected AML, 98% of patients under 60
years received intensive chemotherapy, compared to 78% of
patients aged 60–69 years, 29% of patients 70–79 years and 6% of
patients over 80 years. The relatively high CR rates 80%, 84%,
60% and 50% in the treated patients thus correlate to a marked
selection in the higher age groups. Secondary AML patients
received ‘low-dose’ treatment more often than those with de novo
AML. How factors such as poor performance status and concomi-
tant disease have influenced decisions to refrain from intensive
chemotherapy cannot be quantified in this material. We do not
know if the high exclusion rate from induction chemotherapy had
a good or bad impact on our total survival. Median overall survival
was higher than in previous population-based reports from Sweden
with 24.8 months for patients under 60 years and 3.1 months for
those over 60 years, including unreferred and untreated patients
(Öst et al, 1984; Wahlin et al, 1991).
For patients over 80 years, who in our study constituted 15% of
all AML cases, an adverse effect of intensive chemotherapy on
survival and overall quality of life has been indicated in an earlier
study from the MD Anderson Cancer Center (DeLima et al, 1996).
In our experience, low-dose chemotherapy with thioguanine, ara-C
and etoposide alone or in combination without intention to induce
cytopenia has been of value in some patients, at least in alleviating
symptoms of a high leukaemic cell burden. Whether or not such
therapy prolongs survival significantly in larger patient materials
is under question as AML treatments with palliative intention have
not been studied in a randomized way. Other investigational thera-
pies would also be of interest in this age group (DeLima et al,
1996).
In spite of the heterogeneity of our patient material, we could
confirm the value of some established prognostic factors in AML
in our intensively treated patients. Age has proved to be the most
important factor in many studies (Bernard et al, 1984; Estey et al,
1989; Wahlin et al, 1991). The prognostic impact of age per se is
difficult to evaluate in this study as treatment decisions were
largely based on age and performance status of the patients,
without uniform documentation of the latter. Karyotype has
emerged as the most important feature of AML concerning prog-
nosis, and already has therapeutic consequences in modern AML
treatment (Bernard et al, 1984; Büchner and Heinecke, 1996;
Fenaux et al, 1989; Ferrara et al, 1998). Secondary AML had
worse outcome than de novo AML but did not appear as a selected
prognostic factor in the present investigation probably due to a
strong correlation to the patient age.
Among routinely measured laboratory variables, leucocyte
count (Dutcher et al, 1987; Fenaux et al, 1989), LDH (Büchner and
Heinecke, 1996; Ferrara and Mirto, 1996) and kidney function
tests (Estey et al, 1989; Johnson et al, 1993, 1995) have repeatedly
been assigned prognostic value. Of such variables, LDH and crea-
tinine appeared somewhat stronger than the leucocyte count in the
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correlation was seen between these variables and treatment inten-
sity. Nearly 1/4 of all patients had impaired kidney function at
diagnosis, often unexplained by medical history and reversible
with chemotherapy, suggesting a contributing role of the
leukaemia itself. The prognostic value of kidney function tests in
AML is probably not only related to concomitant other disease or
poor performance status.
In summary, we believe our study to be a unique example of
unselected AML cases. Although the long-term survival at
5 years was as low as 9.3%, some improvement in survival is
shown in comparison with similar earlier studies. The treatment of
an increasing proportion of elderly patients will be a challenge in
the future, where the crucial question of how to predict benefit or
not from intensive chemotherapy needs to be further investigated.
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